CME: Long-term Management of Neovascular AMD: Meeting the Need for Improvement

Author(s)/Faculty: Justis P. Ehlers, MD; Rishi P. Singh, MD
Source: Healio Education Lab – Ophthalmology
CME Provided By: Vindico Medical Education

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment. As prevalence of AMD continues to increase, it is estimated that nearly 3 million individuals in the United States will develop AMD by 2020. The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapies into therapeutic protocols has significantly improved the prognosis for patients with AMD. Unfortunately, initial vision gains are not always maintained; however, continued evaluation of anti-VEGF therapies and treatment protocols are now providing visual acuity gains with long-term therapy. In this educational activity, experts in the field review intravitreal anti-VEGF treatment protocols, discuss outcomes from pinnacle clinical studies, and evaluate recent studies that demonstrate visual acuity benefits with long-term anti-VEGF therapy.

LINK TO CME: Healio Education

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close